Breaking

Novo Nordisk and Anthropic Partner to Use Claude Science in Drug Development

September 16, 2026 at 10:02 EDT

Foundation Models
AI Agents
Healthcare

Novo Nordisk and Anthropic announced a collaboration on September 16, 2026, to use Anthropic models and Claude Science in pharmaceutical R&D, with the stated goal of helping Novo discover and develop medicines faster. The companies said the work will focus on scientific reasoning, drug-discovery workflows and AI-driven software engineering, with data governance and human oversight built into the deployment.

September 16, 2026 · Novo Nordisk and Anthropic

Claude Science moves deeper into pharma R&D

Novo will test Anthropic models and Claude Science on targeted drug-discovery, biological reasoning and AI-driven software engineering workflows, with human oversight and data governance built in.

67,000+

Novo employees worldwide

0.83

Claude Sonnet 4.5 Protocol QA score

99.9%

Earlier documentation time reduction cited by Anthropic

50%

Earlier review-cycle reduction cited by Anthropic

Protocol QA: model, human and prior model

The strongest available benchmark figure in the article compares scores on the same 0-to-1 scale.

0.83

Sonnet 4.5

0.79

Human baseline

0.74

Sonnet 4

Where the collaboration starts

R&D workflowsSpecific tasks selected by Novo teams

→

Claude ScienceScientific reasoning and biological workflows

Governed useHuman oversight and data controls

What supporters see

A practical research layer for literature review, data analysis, protocol drafting, regulatory preparation and software engineering inside existing R&D systems.

What remains hard

AI can speed parts of discovery, but experiments, clinical evidence and regulatory review still determine whether a medicine reaches patients.

Continue reading

The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.